WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six months. The agency is facing a barrage of criticisms over its approval of an as-yet-unproven Alzheimer’s drug. And now critics are calling for the ouster of the acting commissioner.
But speaking to that acting FDA Commissioner, longtime agency vet Janet Woodcock, you’d think everything is peachy.
In a phone call with STAT on Wednesday, Woodcock emphasized that the lack of a permanent commissioner is not hampering the agency’s operations, and that she has the full support of the administration to pursue whatever policies she deems fit.
Create a display name to comment
This name will appear with your comment